Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)

F. Zappa; C. Droege; D. Betticher; R. von Moos; L. Bubendorf; A. Ochsenbein; O. Gautschi; E. Oppliger Leibundgut; P. Froesch; R. Stahel; T. Hess; D. Rauch; P. Schmid; M. Mayer; S. Crowe; P. Brauchli; K. Ribi; M. Pless

Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)

F. Zappa
, C. Droege
, D. Betticher
, R. von Moos
, L. Bubendorf
, A. Ochsenbein
, O. Gautschi
, E. Oppliger Leibundgut
, P. Froesch
, R. Stahel
, T. Hess
, D. Rauch
, P. Schmid
, M. Mayer
, S. Crowe
, P. Brauchli
, K. Ribi
, M. Pless

Careum School of Health

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	239-244
Number of pages	6
Journal	Lung Cancer
Volume	78
Issue number	3
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

Zappa, F., Droege, C., Betticher, D., von Moos, R., Bubendorf, L., Ochsenbein, A., Gautschi, O., Oppliger Leibundgut, E., Froesch, P., Stahel, R., Hess, T., Rauch, D., Schmid, P., Mayer, M., Crowe, S., Brauchli, P., Ribi, K., & Pless, M. (2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05). Lung Cancer, 78(3), 239-244.

@article{ef369f21c3324858bc649713e51be5bf,

title = "Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)",

author = "F. Zappa and C. Droege and D. Betticher and \{von Moos\}, R. and L. Bubendorf and A. Ochsenbein and O. Gautschi and \{Oppliger Leibundgut\}, E. and P. Froesch and R. Stahel and T. Hess and D. Rauch and P. Schmid and M. Mayer and S. Crowe and P. Brauchli and K. Ribi and M. Pless",

year = "2012",

language = "English",

volume = "78",

pages = "239--244",

journal = "Lung Cancer",

number = "3",

}

Zappa, F, Droege, C, Betticher, D, von Moos, R, Bubendorf, L, Ochsenbein, A, Gautschi, O, Oppliger Leibundgut, E, Froesch, P, Stahel, R, Hess, T, Rauch, D, Schmid, P, Mayer, M, Crowe, S, Brauchli, P, Ribi, K & Pless, M 2012, 'Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)', Lung Cancer, vol. 78, no. 3, pp. 239-244.

Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05). / Zappa, F.; Droege, C.; Betticher, D. et al.
In: Lung Cancer, Vol. 78, No. 3, 2012, p. 239-244.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)

AU - Zappa, F.

AU - Droege, C.

AU - Betticher, D.

AU - von Moos, R.

AU - Bubendorf, L.

AU - Ochsenbein, A.

AU - Gautschi, O.

AU - Oppliger Leibundgut, E.

AU - Froesch, P.

AU - Stahel, R.

AU - Hess, T.

AU - Rauch, D.

AU - Schmid, P.

AU - Mayer, M.

AU - Crowe, S.

AU - Brauchli, P.

AU - Ribi, K.

AU - Pless, M.

PY - 2012

Y1 - 2012

M3 - Article

VL - 78

SP - 239

EP - 244

JO - Lung Cancer

JF - Lung Cancer

IS - 3

ER -